Hoffmann-La Roche Limited
$9.1M 60 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. reported $9,115,355.97 across General Payments, Research, and Ownership to 33,978 physicians and teaching hospitals across 34,141 transactions.
- $9.1M Top 10% payer
- All-tracks total
- 34,141 Top 10% volume
- Transactions
- 33,978 Top 10% reach
- Recipients
- #186
- of 1,925 companies
Tarsus Pharmaceuticals, Inc. reported $9,115,355.97 across all CMS Open Payments tracks (General + Research + Ownership) to 33,978 physicians and teaching hospitals in Program Year 2024 - ranking #186 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $5,283,858.20, averaging $268.27 per recipient.
How Tarsus Pharmaceuticals, Inc.'s $9.1M all-tracks total breaks down
Tarsus Pharmaceuticals, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
A
99/100
Total payments
A
94/100
Transaction volume
A
100/100
Physician reach
A
100/100
Payment type diversity
A
100/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer tarsus-pharmaceuticals-inc Tarsus Pharmaceuticals, Inc.
$9.1M · #186/1,925 · 0.1% industry · PY2024
- TOT $9.1M
- RANK #186
- SHARE 0.1%
- TXN 34,141
- RCP 33,978
- CAT 9
- GEN $5.3M
- TOP1 13.5%
- PY 2024
Volume peers
Nearest volume peer: Hoffmann-La Roche Limited ($9.1M)
Tarsus Pharmaceuticals, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Tarsus Pharmaceuticals, Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Tarsus Pharmaceuticals, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
"Consulting Fee" leads the 9-category general-payment breakdown below at $2.2M (41.2% of General Payments, 442 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 9 types of general payments, Tarsus Pharmaceuticals, Inc.'s largest category was "Consulting Fee" at $2.2M - 41.2% of General Payments.
Tarsus Pharmaceuticals, Inc. reports 9 general-payment categories - the top three are Consulting Fee (41.2%), Compensation for Services Other Than Consulting (33.1%), and Food and Beverage (22.4%). The remaining 6 categories make up 3.4% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
Category breadth matters here: Tarsus Pharmaceuticals, Inc. files across 9 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.
How Tarsus Pharmaceuticals, Inc. divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $2.2M | 442 | 41.2% |
| Compensation for Services Other Than Consulting | $1.7M | 390 | 33.1% |
| Food and Beverage | $1.2M | 32,528 | 22.4% |
| Travel and Lodging | $160.8K | 603 | 3.0% |
| Charitable Contribution | $7.0K | 2 | 0.1% |
| Grant | $5.0K | 1 | 0.1% |
| Gift | $2.5K | 10 | 0.0% |
| Space Rental or Facility Fees | $2.0K | 1 | 0.0% |
| Education | $299.00 | 1 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $1,991,841.74 (37.7%) of $5,283,858.20 in this company's General Payments records across 13,477 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Tarsus Pharmaceuticals, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Elizabeth Yeu-Lin
$712,728.88 across 56 reported transactions
- 2
Katherine Goodrich
$628,039.00 across 2 reported transactions
- 3
Andrew Goldberg
$262,883.31 across 23 reported transactions
- 4
Ted Love
$228,366.61 across 14 reported transactions
- 5
Richard Adler
$159,823.94 across 130 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Tarsus Pharmaceuticals, Inc. ranks #186 of 1,925 by total payments (top 10% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,369 of 1,838 by HHI (bottom 26% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Brainsway USA INC : $36.9K total payments, HHI 416
- Erbe USA Inc : $161.0K total payments, HHI 415
- OsteoCentric Technologies, Inc. : $303.4K total payments, HHI 412
- Integrity Implants Inc. dba Accelus : $1.6M total payments, HHI 412
- Provepharm Inc. : $41.4K total payments, HHI 411
- TriSalus Life Sciences, Inc. : $443.3K total payments, HHI 411
- Tarsus Pharmaceuticals, Inc. (this company) : $5.3M total payments, HHI 409
- Roche Diagnostics Corporation : $552.8K total payments, HHI 407
- PROCEPT BioRobotics Corporation : $1.7M total payments, HHI 405
- Cerapedics Inc. : $796.4K total payments, HHI 405
- Shorla Oncology Inc. : $797.92 total payments, HHI 404
- Providence Medical Technology, Inc. : $467.9K total payments, HHI 404
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Tarsus Pharmaceuticals, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Tarsus Pharmaceuticals, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Tarsus Pharmaceuticals, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Tyber Medical, LLC
$9.1M 27 recipients
Compare payment profiles
Eli Lilly Export S.A. Puerto Rico Branch
$9.2M 1,317 recipients
Compare payment profiles
4WEB, Inc.
$8.9M 718 recipients
Compare payment profiles
ConvaTec Inc.
$9.3M 12,574 recipients
Compare payment profiles
CapsoVision, Inc.
$8.9M 776 recipients
Compare payment profiles
Put this to use
Tarsus Pharmaceuticals, Inc. ranks #186 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where Tarsus Pharmaceuticals, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Tarsus Pharmaceuticals, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.